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Abstract
Background In the complex etiology of inflammatory
bowel disease (IBD), the exposome is a major contributor.
Though many environmental exposures have been identi-
fied, quality of evidence varies greatly and overall evidence
for the exposome is inconclusive. A universal, precise, and
reproducible measurement tool is needed to study the
exposome in IBD.
Methods We built the web-based Groningen IBD Envi-
ronmental Questionnaire (GIEQ), an extensive and struc-
tured questionnaire measuring potentially involved
environmental exposures, consisting of 848 items, subdi-
vided into 15 categories. For validation, 76 IBD patients
completed the GIEQ twice (2-month interval). Cohen’s
kappa and correlation coefficients were used to compare
both fills. Internal consistency was evaluated using Cron-
bach’s alpha tests. Proportional bias was examined using
Bland–Altman plots.
Results In general, we obtained a mean kappa coefficient
of 0.78 (standard deviation 0.17) for categorical questions
and a mean intraclass correlation coefficient of 0.88 (0.15)
for numeric questions. Cronbach’s alpha ranged from 0.64
to 1.0 with a mean of 0.79 (0.14). Bland–Altman plots
showed proportional bias only for current physical activity
score.
Conclusions The GIEQ is a reliable measurement tool to
study the exposome in IBD, enabling consistent measure-
ment of an extended number of environmental factors and
their interactions. Use of the GIEQ across IBD cohorts will
lead to more standardized, generalizable, and comparable
results. Also, the GIEQ can be used for calculation of an
exposome risk score, applicable for secondary prevention
by identifying high-risk patients as well as to analyze
interactions between the exposome and other aspects of
IBD etiology.
Keywords Exposome  Environmental factors 
Inflammatory bowel diseases  Questionnaire  Validation
Introduction
Inflammatory bowel disease (IBD), consisting of ulcerative
colitis (UC) and Crohn’s disease (CD), is a gastrointestinal
disease characterized by chronic inflammation [1]. Disease
etiology is complex; besides the clear role of genetic
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susceptibility, increasing evidence indicates an important
role for lifestyle and environment [2–5]. Originally, IBD
was a western lifestyle-mediated disease, with incidence
rates highest in Europe (37.0 per 100,000 person–years)
and the United States (39.4 per 100,000 person–years).
However, with global westernization and changing life-
styles, incidence rates of IBD are now rising in developing
countries as well, making IBD a global health problem [6].
Previously, we presented a comprehensive overview of
the current state of knowledge concerning proposed envi-
ronmental factors forming the exposome [7]. Numerous
environmental exposures, starting at birth, have been
associated with the development of IBD in past studies
[4, 7–9]. Different markers of childhood hygiene, in line
with the hygiene hypothesis, as well as receiving breast-
feeding are shown to be protective against IBD, whereas
antibiotic use during childhood increases risk of CD alone
[10–14]. Later in life, other environmental exposures come
into play, e.g., the use of hormone-containing medications
and non-steroidal anti-inflammatory drugs (NSAIDs),
increasing chances of developing IBD [15–17]. Cigarette
smoking, on the other hand, holds a divergent effect, as a
protective effect is described for UC, while risk of CD
development increases [18]. Physical activity might protect
against CD, but evidence is incoherent [19]. Also, expo-
sures concerning living environment seem to play a role in
disease development regardless of time of exposure, such
as living in southern latitudes as shown by a Scandinavian
study, a high summer temperature, and an increased con-
centration of (predicted) vitamin D, all thought to play a
protective role against development of IBD, opposite to the
potential role of air pollution [20–22].
Although exploring of all these environmental expo-
sures has led to new steps in understanding disease etiol-
ogy, this knowledge was not translated to
recommendations, and clinical applicability has not been
practiced due to a number of limitations. First of all, the
quality of evidence varies greatly among different factors
[7]. Whereas the protective role of breastfeeding has been
shown in a comprehensive meta-analysis, the association of
recently identified factors such as air pollution with IBD
has only been shown in single-center case-controlled or
cohort studies, and replication of results is lacking [22, 23].
Second, different environmental factors are often studied in
different patient cohorts. Consequently, possible interac-
tions within the exposome remain unexamined. Finally, the
role of environmental exposures and the exposome is often
studied without taking the importance of genetic suscepti-
bility into account. Hypothesizing that genetic suscepti-
bility forms the starting point of disease development, each
environmental exposure involved in disease etiology,
starting at birth, forms an additional hit in the complex
process of IBD development.
Since not all identical twins, as well as not all individ-
uals with equal environmental exposures will continue to
develop IBD, interactions between the genome and expo-
some, therefore, have to play a crucial role in disease
development. Whereas knowledge concerning the role of
the genome in disease etiology has improved greatly in the
past years, the exposome has fallen behind [2, 4]. Together
with the microbiome and diet, the exposome and genome
form the basis of the complex model of IBD etiology
(Fig. 1). Given the lack of consistent high quality evidence
for the role of environmental factors for IBD, subsequent
steps have to be taken to fill these gaps in the understanding
of disease etiology and to provide sufficient and convincing
evidence supporting the role of the exposome in IBD and
thus for its clinical applicability. Possibly involved envi-
ronmental exposures forming the exposome should com-
prehensively be measured in large, well-documented study
populations using a validated and universally applicable
tool. Ultimately, an exposome risk score (ERS) could be
build, following in the footsteps of the genetic risk score
(GRS) [2, 24].
Whereas measurement methods of the genome are very
consistent and comparable across IBD cohorts, and were
standardized and harmonized by consortia, due to using
common array technologies and calling methodologies, a
comprehensive measurement method for the exposome is
lacking. Previous studies have used the environmental
factors scheme of the International Organization of
Inflammatory Bowel Disease (IOIBD) [8]. However, this
questionnaire is inapplicable for studying a westernized
population due to i. subject selection (i.e., sanitary condi-
tions and childhood vaccinations), as there will be little to
no differences across these examined factors within patient
cohorts, and ii. the fact that several (recently) described
factors are not included in this questionnaire. Therefore, to
further our understanding of the role of the exposome, the
first step consists of the formation of an IBD-specific,
reliable, reproducible, and universally applicable mea-
surement tool to examine the exposome across IBD
cohorts. Therefore, we have built and validated the
Groningen IBD Environmental Questionnaire, hereafter
referred to as the GIEQ, evaluating a comprehensive of
possibly involved exposures. Combining both entities of
ERS and GRS will possibly lead to the identification of
individuals at risk for IBD, an earlier diagnosis when
symptoms occur in high-risk individuals, development of
recommendations for lifestyle in at risk individuals, and





To build a reliable and reproducible measurement tool to
study the exposome in IBD, a number of consecutive steps
have been followed, which will be discussed in chrono-
logical order (Fig. 2).
Step 1: Identification of potential environmental
factors
In building the GIEQ, we cooperated with the LifeLines
study and biobank in Groningen, the Netherlands. LifeLi-
nes is a multi-disciplinary prospective population-based
cohort study examining in a unique three-generation
design, the health and health-related behaviors of 167,729
persons living in the North of the Netherlands. It employs a
broad range of investigative procedures in assessing the
biomedical, socio-demographic, behavioral, physical, and
psychological factors which contribute to the health and
disease of the general population, with a special focus on
multi-morbidity and complex genetics. Questionnaire
domains were selected, based on current knowledge of
already known environmental factors, as summarized in
our review, and possibly involved, novel environmental
factors, allowing us to study and discover yet unknown
environmental risk factors involved in IBD [7, 26]. An
overview of selected domains, ordered over time, is shown
in Fig. 1.
Step 2: Development and content of the GIEQ
Next, all domains were sorted into 15 categories. Questions
examining these domains were either selected from the
previously validated questionnaires used in the LifeLines
cohort and biobank study, or newly formulated by us [26].
Questions were either categorical, numeric, or narrative
Fig. 1 Role of the Groningen IBD Environmental Questionnaire in disease etiology
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text, and ordinal answering categories were used when
applicable. Often, questions are asked for two distinct time
points, once to examine the exposure before disease diag-
nosis, once for the time at study recruitment of the patient.
Overall, the GIEQ consists of 848 items (587 categorical,
228 numeric, and 33 narrative items), spread over 15 cat-
egories: general (18 items), birth and development (13),
family health (141), work and education (21), living
environment (47), sleep (48), physical activity (114), stress
(52), health (78), allergy (24), medication use (37), ques-
tions for females (16), lifestyle (110), detergents (28), and
character (101). Examples of questions are further descri-
bed in the results section and Online supplementary
material—the GIEQ.
The questionnaire was then evaluated for meeting its
aim, its content, structure consistency, and persistency, and
its contextual coherence. All individual questions including
answering categories and source are presented in the online
supplementary material—the GIEQ.
Step 3: Readability of the GIEQ (pilot study)
To test for readability, duration, and clarity of the GIEQ for
IBD patients, a hardcopy of the GIEQ was distributed
among ten IBD patients from the specialized IBD-Center at
the University Medical Center Groningen, the Netherlands.
Patients were selected at random from the 1000IBD cohort
of the UMCG, and were asked to fill the GIEQ with special
attention to usability, difficulty in reading, incomprehen-
siveness of questions, options offered for each question,
and time spent to complete questionnaire. Whereas overall
evaluation of the questionnaire was positive and compre-
hensive, taking approximately 60 min to be completed,
patients mainly commented on the lack of appropriate
answering categories for a number of questions. All com-
ments were evaluated and recommendations were accom-
modated accordingly to specified questions.
Step 4: Digitizing the GIEQ
A web-based questionnaire offers patients a more conve-
nient way of participating in a questionnaire-based study,
accompanied by a decreased chance of filling errors, due to
the smart web application design. Wrongful answers are
minimized by only unfolding follow-up questions when
appropriate based on previous answers. When a patient
indicates that a certain exposure is not applicable to him or
her, follow-up questions will not appear. For numeric
questions, clear range borders are set, to prevent impossible
answers. Together, a web-based version of the GIEQ offers
a more reliable method of data collection and minimizing
possible subjective errors and also decreasing the overall
duration of filling the questionnaire, hindering the source of
biases. Therefore, the GIEQ was digitized in close coop-
eration with experts in developing online tools at the
Research Data Support (RDS) unit at UMCG. Strict steps
have been undertaken to keep privacy of patients secured
based on ethical and scientific integrity guidelines of the
UMCG. After digitizing the GIEQ, questions were checked
again for their accuracy.
Fig. 2 Flowchart of development of the GIEQ
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Step 5: Validation of the GIEQ
Once formation of the GIEQ was completed from steps
1–4, several steps have been undertaken to test for relia-
bility and reproducibility.
Step 5a: Formation of a validation cohort
The first 300 patients of the 1000IBD cohort at the UMCG
were invited to participate in the GIEQ-study. This IBD
cohort consists of patients treated in the IBD-Center of the
Department of Gastroenterology and Hepatology of the
UMCG for whom extensive multi-omics information has
been collected including, among others, genome, tran-
scriptome, microbiome, and dietary information. Patients
are prospectively followed, and extensive information on
disease diagnosis and course is collected during routine
visits to the IBD center. (Imhann et al., submitted) Patients
were invited to participate by letter or phone call.
Approximately 70% of invited patients initially enrolled,
after which 148 patients completed the GIEQ. These 148
patients were all asked to fill the GIEQ a second time,
approximately 2 months after receiving their first filled
GIEQ, after which a validation cohort was formed (N:76).
Due to the possibility of selection bias, baseline charac-
teristics and the Montreal classification (up to time of
survey) of the validation cohort were compared to the
remaining IBD cohort, using chi-square tests for categori-
cal variables and Kruskal–Wallis H tests for continuous
variables. The results are shown in Table 1. Compared to
the complete IBD cohort, patients of the validation cohort
were statistically significantly older, accompanied by a
longer mean disease duration. These differences are not
likely to influence questionnaire validation results.
Step 5b: Questionnaire validation
Next, all individual questions forming the GIEQ were
evaluated for reliability and reproducibility by comparing
the first fill (Q1) to the second fill 2 months later (Q2), for
each of the 76 individuals. Descriptives and distribution of
each question was checked. Clear outliers and impossible
answers (e.g., working 8 days per week) were excluded
from further analysis. For categorical questions, Cohen’s
kappa coefficients were calculated to determine level of
agreement between Q1 and Q2. As standard practice,
questions scoring a kappa coefficient above 0.6 were
deemed valid [27–29]. In categorical questions with five or
more answer possibilities, answering categories plus and
minus one category were deemed equal. For continuous
questions, either Pearson or Spearman correlation coeffi-
cients, based on variable distribution, were applied to
correlate questions answers between Q1 and Q2 per each
question. A cutoff value of 0.6 was set also, above which
questions were deemed valid. In addition, the Intraclass
Correlation Coefficients (ICC) were calculated for contin-
uous variables. When correlation was low, Bland–Altman
plots were used to examine the possibility of proportional
bias [30]. Independent questions with low reliability were
removed from further analysis and the GIEQ, questions
which were part of a series of questions of a given domain
(for example daily physical activity) and had a low indi-
vidual reliability could not be excluded. Mann–Whitney
U tests were used to examine possible differences in reli-
ability when items were used twice, to assess time before
disease diagnosis and the time at interview. To determine
internal consistency of the GIEQ, Cronbach’s alpha was
determined if possible, and a mean was calculated per
category. Statistical tests chosen for each question of the
GIEQ individually and its results are presented in the
online supplementary material—the GIEQ. Finally, to
further analyze the consistency of responses between the
GIEQ and data collection by patient interviews by treating
physicians, we compared a subset of results of the GIEQ to
available matching data, separately collected in the longi-
tudinal and prospective 1000IBD cohort, using kappa and
Spearman correlation coefficients.
Results
Overall, a mean Cohen’s kappa coefficient of 0.78 for all
584 categorical items (standard deviation 0.17) was
achieved, indicating a substantial level of agreement.
However, large variation exists between questionnaire
categories, ranging from 0.68 (0.16) for medication use
indicating moderate agreement to 0.92 (0.13) for items
concerning birth and development, indicating almost per-
fect agreement. A mean overall correlation coefficient of
0.85 (0.16) was found for all 215 numeric items, ranging
from a mean of 0.62 (0.11) of items concerning physical
activity, to 1.00 (0.00) when family health involving ones’
children is reviewed. Figure 3 displays an overview of
either Cohen’s kappa coefficient or correlation coefficients
of each individual item, sorted per category. An overview
of validation statistics per category is shown in Table 2.
Due to the differences between categories, all will be dis-
cussed separately below.
In the general category, items mainly concern demo-
graphic information and, e.g., weight. With a mean
Cohen’s kappa coefficient of 0.86 (ranging from 0.68 to
1.00) in categorical variables and a mean correlation of
0.95 (0.84–1.00) for continuous variables, sufficient
agreement was obtained.
When focusing on birth and development, items ranging
from weight at birth to receiving breastfeeding or formula
J Gastroenterol
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as an infant, a mean Cohen’s kappa coefficient of 0.88
(0.69–1.00) was gained. Continuous variables showed a
high correlation of 0.95 (0.78–1.00).
For items concerning family health, a clear difference
was observed when comparing items concerning ones’
children (Cohen’s kappa coefficient of 0.85, 0.55–1.00) to
ones siblings (0.70, - 0.10–1.00), although low numbers
of (positive) answers might decrease the coefficient
dramatically. Therefore, caution is needed when sibling
health is evaluated by the GIEQ in further studies.
When evaluating education and work, a mean Cohen’s
kappa coefficient of 0.85 (0.52–1.00) was shown. In this
category, separate analysis of items concerning the time
before disease diagnosis (0.85, range of 0.64–1.0) and the
current situation (0.84, 0.52–1.00), shows no difference in
Table 1 Baseline
characteristics of the validation
cohort in comparison to the
1000IBD cohort
IBD cohort Validation cohort
N: 1341 N: 76
Agea Mean ± SD 45.7 (15.7) 51.5 (13.2)
Sex
Male n (%) 562 (41.9) 35 (46.1)
Female n (%) 779 (58.1) 41 (53.9)
IBD type
Crohn’s disease n (%) 699 (52.1) 38 (50.0)
Ulcerative colitis n (%) 570 (42.5) 36 (47.4)
IBD unclassified n (%) 72 (5.4) 2 (2.6)
Disease durationa Mean ± SD 15.8 (10.2) 19.1 (11.0)
History of cigarette smoking n (%) 733 (54.8) 42 (57.5)
Montreal classification
Age at diagnosis
\ 16 years n (%) 191 (14.2) 9 (11.8)
17–40 years n (%) 847 (63.2) 44 (57.9)
[ 40 years n (%) 299 (22.3) 23 (30.3)
Disease location (CD)
Ileal disease n (%) 249 (35.6) 11 (28.9)
Colonic disease n (%) 144 (20.6) 9 (23.7)
Ileocolonic disease n (%) 287 (41.1) 18 (47.4)
(Isolated) upper GI-disease n (%) 71 (10.2) 3 (7.9)
Disease behavior (CD)
Inflammatory n (%) 342 (48.9) 13 (34.2)
Structuring n (%) 231 (33.0) 14 (36.8)
Penetrating n (%) 111 (15.9) 11 (28.9)
Perianal disease n (%) 207 (30.3) 12 (31.6)
Disease extent (UC)
Proctitis n (%) 58 (10.2) 3 (8.3)
Left sided UC n (%) 167 (29.3) 16 (44.4)
Extensive UC n (%) 300 (52.6) 14 (38.9)
Disease severity (UC)
Asymptomatic n (%) 36 (6.3) 1 (2.8)
Mild UC n (%) 151 (26.5) 13 (36.1)
Moderate UC n (%) 187 (32.8) 12 (33.3)
Severe UC n (%) 137 (24.1) 6 (16.7)
Complicated disease course
Need for biologicals n (%) 492 (36.8) 20 (26.7)
Need for surgery n (%) 442 (33.0) 32 (42.1)
aIndicates a level of significance\ 0.01
SD indicates standard deviation, number and (percentages) as n indicated n (%)
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agreement as was tested with a Mann–Whitney test
(p value 0.74).
When addressing living environment, items concerning
childhood pets and living surroundings (e.g., rural versus
urban), among others, we got a mean agreement of 0.74
(- 0.02–1.00). As mentioned before, in sub questions, a
low number of (positive) responses also might decrease the
observed Cohen’s kappa coefficient drastically.
For analyzing sleep, a mean agreement of 0.71
(0.56–0.79) and 0.67 (0.46 – 0.85) was observed for cate-
gorical and continuous items, respectively. With a mean
ICC of 0.80 (0.60–0.92), however, substantial agreement
was obtained. When comparing items concerning time
before diagnosis (Cohen’s kappa coefficient 0.74,
0.72–0.78, correlation coefficient 0.60, 0.46–0.78) to items
evaluating the present (0.70, 0.56–0.79 and 0.77,
0.67–0.85), no significant difference was observed for
either categorical items (p value 0.51) nor continuous items
(p value 0.25). Bland–Altman plots showed no evidence for
proportional bias. Please see online supplementary material
2—Bland–Altman plots, for all individual plots.
Examining physical activity (PA) is previously shown to
be difficult [19]. Using the Short Questionnaire to ASses
Health (SQUASH) evaluating PA, a mean correlation of
0.62 (0.48–0.82), measured by Spearman coefficients was
retained, comparable to the previous results of the
SQUASH deemed valid [31]. Since zero activity in highly
unlikely, participants with a zero-activity score were
excluded from analysis due to the high likelihood of
incorrect answering. ICC showed a similar agreement of
0.60 (0.34–0.82). When comparing agreement between
applying the SQUASH to time before disease diagnosis
(0.60, 0.48–0.82) and at the time of interview (0.64,
0.53–0.72), no significant differences were found (p value
0.34). Bland–Almont plots showed proportional bias for
total PA score before disease diagnosis (p value 0.03), but
not on present PA score (p value 0.38).
Sum scores evaluating stress as caused by unpleasant
life-events showed a mean agreement of 0.78 (0.75–0.84),
with no significant difference when comparing time before
disease (0.76, 0.76–0.76) to time at interview (0.80,
0.75–0.84, p value 1.00).A mean ICC of 0.87 (0.85–0.91)
Fig. 3 Reliability of individual GIEQ items, stratified by category
J Gastroenterol
123
was observed, with no indication of proportional bias, as
shown by Bland–Altman plots.
Items evaluating health primary focus on symptoms of
other autoimmune diseases, such as bronchial hypersensi-
tivity, eczema, alopecia and vitiligo. A mean agreement of
0.73 (0.27–1.00) and 0.92 (0.62–1.00) was found for cat-
egorical and continuous items, respectively.
Food allergies were analyzed separately, for which a
mean agreement for categorical items of 0.84 (0.49–1.00)
was found. This category does not contain continuous
items.
Medication use assesses the use of over the counter
medications, with extra focus on analgesics and food sup-
plements such as fish oil and vitamin D. A low agreement
of 0.52 (0.05–0.96) is found when all items are combined.
Separate evaluation of items assessing time before (0.60,
0.32–0.96) and after (0.44, 0.05–0.68) diagnosis shows no
significant difference (p value 0.08), although a trend
seems present. Only a subset of items assessing the amount
of analgesics in the year before diagnosis shows convincing
agreement (0.88, 0.82–0.96). All other items have been
excluded from the GIEQ.
Questions for women, concerning the menstrual cycle
and the use of hormone-containing medications have
shown a good overall agreement for categorical (0.79,
0.5–1.00) and numeric (0.89, 0.72–1.00) questions.
Items evaluating several different aspects of lifestyle,
varying from watching television to alcohol and drug use,
show a good overall agreement of 0.84 (0.48–1.00) and
0.92 (0.75–1.00) for categorical and continuous items,
respectively.
Use of detergents covers exposure to toothpaste and
dishwashing soap, among others. Overall agreement of
categorical (0.84, 0.48–1.00) as well as continuous items
(0.92, 0.75–1.00) was shown to be sufficient.
Table 2 Validation data per
each of the 15 categories
constituting the GIEQ
Kappa (SD) R (SD) ICC (SD) Cronbach’s a No. of itemsa
General 0.86 (0.12) 0.95 (0.06) 0.95 (0.09) 14
Birth and development 0.92 (0.13) 0.92 (0.14) 0.93 (0.14) 13
Family 0.79 (0.17) 0.97 (0.09) 0.98 (0.04) 0.92 128
General 0.82 (0.07) 0.97 (0.04) 0.98 (0.02) 10
Parents 0.79 (0.16) 1.00 (0.00) 1.00 (0.00) 62
Children 0.85 (0.16) 0.99 (0.01) 0.99 (0.02) 21
Siblings 0.76 (0.21) 0.95 (0.14) 0.97 (0.07) 35
Work and education 0.85 (0.15) – – 0.84 18
Living environment 0.77 (0.16) 0.92 (0.09) 0.95 (0.05) 44
Sleep 0.72 (0.07) 0.68 (0.16) 0.80 (0.12) 0.78 15
Physical activity 0.77 (0.00) 0.62 (0.11) 0.60 (0.14) 16
Stress – 0.78 (0.04) 0.87 (0.03) 0.64 4
Health 0.71 (0.18) 0.87 (0.15) 0.90 (0.10) 0.78 76
Allergies 0.81 (0.22) – – 10
Medication use 0.68 (0.16) 0.85 (0.12) 0.92 (0.08) 0.74 15
Questions for females 0.79 (0.21) 0.92 (0.07) 0.94 (0.06) 12
Lifestyle 0.83 (0.16) 0.93 (0.08) 0.94 (0.05) 1.00 51
Watching television – 0.82 (0.01) 0.90 (0.01) 2
Smoking 0.83 (0.14) 0.93 (0.07) 0.95 (0.06) 17
Use of alcohol 0.80 (0.14) – – 6
Drug use 0.83 (0.21) 0.99 (0.02) 0.97 (0.04) 17
Traveling 0.93 (0.05) – – 4
Sun exposure 0.79 (0.11) – – 5
Detergents 0.79 (0.13) 0.84 (0.07) 0.91 (0.04) 10
Characterb – 0.75 (0.08) 0.87 (0.05) 0.74 9
aBased on number of variables included in validation analysis, does not equal number of GIEQ items since
often sum scores are used
bBased on sum scores calculated from a 64-item character questionnaire
SD indicates standard deviation, ICC indicates intraclass correlation coefficient, R indicates the mean
correlation coefficient, either Spearman or Pearson, based on normality of the tested variable, P indicates
the level of significance
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At last, character was assessed by using the NEO
character questionnaire. Whereas agreement of individual
questions was low (0.37, 0.02–0.74), when these 64 items
were combined in sum scores of eight different personality
traits (competence, anger-hostility, self-consciousness,
impulsivity, excitement seeking, self-discipline, vulnera-
bility, and deliberation), agreement increased greatly (0.77,
0.67–0.88). Supplementary Fig. 1 provides the reliability
of individual items per category.
Supplementary Table 1 displays comparison of the
outcomes as measured by the GIEQ to comparable,
prospectively collected data in the 1000IBD cohort. With a
mean reliability of 0.89 (0.78–1.0), almost perfect agree-
ment is shown.
Discussion
We present a validated, universal measurement tool to
evaluate the exposome in patients with IBD. Whilst some
categories have proven to be more reliable than others,
overall reliability and reproducibility are substantial. Level
of reliability of each individual question and attributing
category can to be taken into account when interpreting
future results of the GIEQ. Altogether, the GIEQ is shown
to be a reliable tool to measure environmental exposures in
IBD, is readily available to the research community, and
can be used to study the role of the exposome and novel
environmental factors in IBD.
Whereas the role of the genome has been subject to
extensive research already, the exact role of the exposome
remains unclear. Therefore, future studies should focus on
the role of the exposome. In order to acquire generalizable
results and enable comparison between different study
cohorts, one extensive measurement tool should be used
world-wide. The GIEQ will be used in the 1000IBD cohort
previously mentioned, providing insight in the role of
environmental factors on disease development by evalua-
tion of exposures before diagnosis as well as their role in
disease course by evaluation of current exposures. Fur-
thermore, the GIEQ offers the unique opportunity to
compare IBD data with 167,000 population-based indi-
viduals from the LifeLines study living in the same geo-
graphic region. This allows previously identified as well as
so far unknown potentially involved environmental factors
to be analyzed. The GIEQ provides the opportunity to
measure a large amount of environmental exposures all at
once, allowing analysis of interactions between different
environmental exposures, as different exposures seem to
have similar biological modus of effect. Gut permeability
for example, seems to be affected by the use of non-ster-
oidal anti-inflammatory drugs (NSAIDs) as well as smok-
ing cigarettes [32, 33]. One can imagine that combining
both exposures will yield a different effect than that of
individual evaluation per each factor.
As with all questionnaire-based research, the GIEQ has
its limitations. Recall bias might lead to wrongful or
incomplete answering, with increasing risk for questions
concerning the past (e.g., before diagnosis of IBD), espe-
cially in older patients. However, since our validation
cohort was significantly older, accompanied by an
increased disease duration, when compared to the complete
IBD cohort, it is conceivable that the results of our vali-
dation analyses are accurate, if not an underestimate of
actual reliability. As the results have shown, we observed
proportional bias for the calculated activity scores. This is
likely due to better understanding of the used SQUASH-
format in the second fill, leading to better completion and
therefore higher activity scores. In future use of the ques-
tionnaire, this has to be taken into account. Due to the size
of our validation cohort, separate validation for certain
subgroups of patients (e.g., men versus women or different
age groups) was not feasible. However, there is no evi-
dence that the results of validation might have been dif-
ferent in subgroups than in the whole cohort, and according
to found results, the sample size is sufficient. Our strategy
to develop the GIEQ was to be as inclusive as possible, in
sense of including comprehensive items assessing any
known potentially involved environmental factor. Though,
this may lead to a longer duration of completing the GIEQ.
Patients use approximately an hour to fill the web-based
questionnaire, which may lead an unwitting lack of preci-
sion and consistency in filling the questionnaire and thus
introducing information and attrition bias when generating
large study cohorts by using GIEQ. However our validation
shows good equality between first and second measure-
ments suggesting consistent answers to questions by
patients. Also, to reduce this limitation, the web-based
GEIQ was designed with an automatic save function at any
given moment. Patients may stop filling the questionnaire
for any reason at any time, and proceed at a later time
point, without the loss of work. Finally, a Dutch version of
the GIEQ was used, due to our Dutch patient cohort.
However, an English translation of the GIEQ is readily
available and can be validated in and used for studying
English speaking IBD cohorts using our validation meth-
ods. As previous studies have shown differences in the role
and impact of different factors of the exposome between
Asian and Western study populations, the need for a uni-
versal study method is further clarified. [8, 9, 34] Future
studies world-wide using the GIEQ are therefore strongly
encouraged.
As past research in the field of genetics has thought us,
the exposome should not be studied solitary. To examine
IBD etiology as a whole, future studies should be focused
on multiple levels of information. Within the UMCG, this
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view led to a multi-omics approach and the 1000IBD
cohort. (Imhann et al., submitted) Due to the study design
of the 1000IBD cohort, a prospective cohort in which over
a thousand participants are monitored, and data is collected
on phenotype, microbiome and genome, addition of the
GIEQ allows genome-exposome and microbiome-expo-
some interaction analysis. Combining all these will not
only give new insights into IBD etiology but will also be
aimed at discovering biomarker profiles and treatment
targets and will form an important step in progression of
IBD research. The GIEQ forms an important step towards
this goal.
At present, it becomes more evident that while genomic
information alone may not explain disease susceptibility
and shows little predictability of IBD in the general pop-
ulation, there is an increasing need to comprehensively
measure environmental factors in a standardized and har-
monized fashion. The GIEQ is among the first feasible
tools able to measure an extended number of environ-
mental factors, with a convenient level of reliability and
reproducibility, whilst universally applicable to examine
the exposome across IBD cohorts. Implementation of the
GIEQ offers the chance to collect standardized information
concerning the exposome in IBD and opens the possibility
to perform large-scale meta exposome association studies
to further understand the pathogenesis of IBD and improve
the predictability of the occurrence of IBD and its course.
Besides using the GIEQ for secondary prevention by
identifying patients with a high-risk exposome profile,
lessons learned by studying IBD cohorts can be applied to
the general population. Primary prevention might become a
possibility when persons at risk for disease development
can be identified based on a high exposome risk score
combined with genetic susceptibility for disease develop-
ment, as is particularly important in westernizing countries
around the world.
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